Status:
COMPLETED
A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination
Lead Sponsor:
Elpen Pharmaceutical Co. Inc.
Conditions:
COPD
COPD Exacerbation
Eligibility:
All Genders
18-80 years
Brief Summary
Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) combination is commonly prescribed to treat COPD; we will perform a retrospective analysis on the effect of adding a long-acting muscarinic r...
Detailed Description
According to the current guidelines for the treatment of COPD, it is recommended to use combination therapies with different or complementary mechanisms of action . Data suggest that open triple thera...
Eligibility Criteria
Inclusion
- Inclusion
- Patients with COPD who started treatment with a fixed combination of fluticasone / salmeterol via the Elpenhaler® device after 01/01/2012 and were treated continuously for at least 1 year during the recording period.
- Patients for whom spirometric data are available per monitoring year during recording.
- Patients for whom exacerbation data are available per monitoring year during recording.
- Exclusion
- •Patients with asthma
Exclusion
Key Trial Info
Start Date :
May 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03858348
Start Date
May 1 2019
End Date
December 31 2019
Last Update
February 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Papanikolaou Hospital of Thessaloniki
Thessaloniki, Greece